Safety of pembrolizumab (pem) in patients (pts) who stopped ipilimumab (ipi) due to immune-related adverse events Meeting Abstract


Authors: Shoushtari, A. N.; Postow, M. A.; Horvat, T. Z.; Adel, N. G.; Dang, T.; Chapman, P. B.
Abstract Title: Safety of pembrolizumab (pem) in patients (pts) who stopped ipilimumab (ipi) due to immune-related adverse events
Meeting Title: 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 33
Issue: 15 Suppl.
Meeting Dates: 2015 May 29-Jun 2
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2015-05-20
Language: English
ACCESSION: WOS:000358036904046
PROVIDER: wos
Notes: Meeting Abstract: e20023 -- Source: Wos
MSK Authors
  1. Michael Andrew Postow
    175 Postow
  2. Paul Chapman
    240 Chapman
  3. Nelly G Adel
    40 Adel
  4. Thu-Oanh Thi Dang
    9 Dang
  5. Troy Zachery Horvat
    12 Horvat